Literature DB >> 23142195

Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug?

Konstantinos Z Vardakas1, Petros I Rafailidis, Athanasios A Konstantelias, Matthew E Falagas.   

Abstract

OBJECTIVE: To study the predictors of mortality among patients with multi-drug resistant Gram negative (MDRGN) infections and the role of MDRGN bacteria in the outcome of such patients.
METHODS: PubMed and Scopus databases were searched (until June 30, 2012). Data were extracted and analyzed using the technique of meta-analysis.
RESULTS: 30 studies (25 retrospective) were included in the analysis; 9 provided data on predictors of mortality for MDRGN infections only, while 21 provided data for MDRGN vs non-MDRGN infections. Acinetobacter spp were the most commonly studied bacteria followed by Pseudomonas aeruginosa and Enterobacteriaceae. Significant diversity was observed among studies regarding the evaluated predictors of mortality. Infection severity and underlying diseases were the most commonly reported independent predictors of mortality followed by multidrug resistance, inappropriate treatment and increasing age. In studies that included only patients with MDRGN infections, cancer (RR 1.65, 95% CI 1.13-2.39) and prior or current ICU stay (1.27, 1.02-1.56) were associated with mortality. In studies that included patients with MDRGN and non-MDRGN infections, septic shock (3.36, 2.47-4.57), ICU stay (2.15, 1.45-3.20), pneumonia (1.65, 1.09-2.52), isolation of MDRGN bacteria (1.49, 1.21-1.83), inappropriate definitive (2.05, 1.12-3.76) and empirical treatment (1.37, 1.25-1.51), and male gender (1.13, 1.05-1.21) were most commonly observed in patients who died than patients who survived.
CONCLUSION: Significant diversity and statistical heterogeneity was observed. Beyond comorbidity and severity scores, MDR and inappropriate treatment were also identified as predictors of mortality.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23142195     DOI: 10.1016/j.jinf.2012.10.028

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  43 in total

1.  Understanding why resistant bacteria are associated with higher mortality in ICU patients.

Authors:  François Barbier; Thiago Lisboa; Saad Nseir
Journal:  Intensive Care Med       Date:  2015-11-12       Impact factor: 17.440

2.  Risk factors for sepsis in patients with struvite stones following percutaneous nephrolithotomy.

Authors:  Xiaomin Gao; Chaoyue Lu; Fei Xie; Ling Li; Min Liu; Ziyu Fang; Zeyu Wang; Shaoxiong Ming; Hao Dong; Rong Shen; Yinghao Sun; Yonghan Peng; Xiaofeng Gao
Journal:  World J Urol       Date:  2019-04-09       Impact factor: 4.226

3.  Tracking colistin-treated patients to monitor the incidence and outcome of carbapenem-resistant Gram-negative infections.

Authors:  Sameer S Kadri; Samuel F Hohmann; E John Orav; Stephanie L Bonne; Matthew A Moffa; Joseph G Timpone; Jeffrey R Strich; Tara Palmore; Kenneth B Christopher; Christy Varughese; David C Hooper; Robert L Danner
Journal:  Clin Infect Dis       Date:  2014-09-22       Impact factor: 9.079

Review 4.  Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients.

Authors:  Elisabeth Paramythiotou; Christina Routsi
Journal:  World J Crit Care Med       Date:  2016-05-04

5.  Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.

Authors:  Erin M Winstead; Patrick D Ratliff; Ryan P Hickson; Joseph E Mueller; William R Judd
Journal:  Int J Clin Pharm       Date:  2016-06-22

6.  Timeline of health care-associated infections and pathogens after burn injuries.

Authors:  David van Duin; Paula D Strassle; Lauren M DiBiase; Anne M Lachiewicz; William A Rutala; Timothy Eitas; Robert Maile; Hajime Kanamori; David J Weber; Bruce A Cairns; Sonia Napravnik; Samuel W Jones
Journal:  Am J Infect Control       Date:  2016-10-11       Impact factor: 2.918

7.  Risk of drug resistance in repeat gram-negative infections among patients with multiple hospitalizations.

Authors:  Mansi Agarwal; Elaine L Larson
Journal:  J Crit Care       Date:  2017-09-18       Impact factor: 3.425

8.  Whence Resistance?

Authors:  Christopher A Guidry; Stephen W Davies; Rosemarie Metzger; Brian R Swenson; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2015-07-17       Impact factor: 2.150

9.  In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Authors:  A Walkty; H Adam; M Baxter; A Denisuik; P Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 10.  Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned.

Authors:  David van Duin; David L Paterson
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.